PDX Model Cohort
Pancreatic Cancer PDX Models
A meticulously curated bank of Pancreatic Cancer PDX models, directly established from patient biopsies, featuring well-documented treatment histories, genomic mutations, and clinical characteristics.
Summary
Champions Oncology offers 79* clinically relevant Pancreatic Cancer PDX models for oncology pharmacology studies and drug development, derived from late-stage, primary, and metastatic tumors, with many patients having received prior Standard of Care therapies. Most models have been characterized by Next Generation Sequencing (77* with WES, 74* with RNA-seq, and 72* with both) and in vivo drug response testing, providing a comprehensive dataset to evaluate biomarkers of response and non-response in pancreatic cancer. More details on these models can be accessed via Champions’ Model Select®.
(*Model numbers fluctuate as our dataset continuously evolves.)
Champions' leading Pancreatic Cancer PDX Models cohort showcases primary models, each reflecting key clinical characteristics, mutations, and pretreatment history.
Access to one of the largest bank of pancreatic cancer PDX models with clinically relevant molecularand pathological characteristics on the market.
Access to highly characterized PDX models with High Complexity Flow Cytometry, WES, RNAseq, Proteomics and Phosphoproteomics.
Includes models pretreated with advanced therapies like s erlotinib, 5 fluorouracil / irinotecan / oxaliplatin combination therapy or gemcitabine/Nab-paclitaxel combination therapy.
Clinically Relevant Models
Living & diverse bank of clinically relevant models that correlate with clinical outcomes
Pretreated PDX Models
Established from tumor biopsies from patients pretreated with latest generation therapies
Multi-omic Characterization
Clinical annotations coupled with molecular datasets and in vivo responses